Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04 October 2023 - 10:30PM
Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer, today announced
that three abstracts have been accepted for poster presentation at
the upcoming AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics in Boston on October 13, 2023.
“We look forward to presenting the latest
findings from our emerging next-generation farnesyl transferase
inhibitor (FTI) program at this year’s AACR-NCI-EORTC International
Conference,” said Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer of Kura Oncology. “These promising preclinical
data further support the rationale for combining KO-2806 with
distinct classes of targeted therapies, including tyrosine kinase
inhibitors (TKIs), KRASG12C inhibitors and KRASG12D inhibitors.
These findings illustrate the potential for FTIs to drive enhanced
antitumor activity and address mechanisms of innate and adaptive
resistance to targeted therapies.”
Session titles and information for the three
abstracts are listed below. Full abstract details will be available
to registrants via the AACR conference app on October 4, 2023 at
12:00 PM ET.
KO-2806, a next-generation
farnesyltransferase inhibitor, potentiates the antitumor activity
of cabozantinib in clear cell renal cell carcinoma
modelsSession Date and Time: Friday, October 13, 2023;
12:30 PM - 4:00 PM ETSession and Location: Poster Session B, Level
2, Exhibit Hall D Poster Number: B024
The next generation farnesyltransferase
inhibitor, KO-2806, blocks oncogenic signaling at multiple nodes to
enhance the antitumor efficacy of
KRASG12C inhibitor adagrasib in
KRASG12C non-small cell lung
carcinomaSession Date and Time: Friday, October 13, 2023;
12:30 PM - 4:00 PM ETSession and Location: Poster Session B, Level
2, Exhibit Hall D Poster Number: B025
The next-generation farnesyltransferase inhibitor
KO-2806 constrains compensatory signaling reactivation to deepen
responses to KRASG12D
inhibitionSession Date and Time: Friday, October
13, 2023; 12:30 PM - 4:00 PM ETSession and Location: Poster Session
B, Level 2, Exhibit Hall DPoster Number: B023
Copies of the presentations will be available in
the Posters and Presentations section on Kura’s website following
presentation at the conference.
About Kura Oncology
Kura Oncology is a clinical-stage
biopharmaceutical company committed to realizing the promise of
precision medicines for the treatment of cancer. The Company’s
pipeline consists of small molecule drug candidates that target
cancer signaling pathways. Ziftomenib is a once-daily, oral drug
candidate targeting the menin-KMT2A protein-protein interaction for
the treatment of genetically defined acute myeloid leukemia (AML)
patients with high unmet need. Kura is currently enrolling patients
in a Phase 2 registration-directed trial of ziftomenib in
NPM1-mutant relapsed or refractory AML (KOMET-001). The Company is
also conducting a series of studies to evaluate ziftomenib in
combination with current standards of care, beginning with
venetoclax/azacitidine and standard induction
cytarabine/daunorubicin chemotherapy in NPM1-mutant and
KMT2A-rearranged newly diagnosed and relapsed/refractory AML
(KOMET-007). Tipifarnib, a potent and selective FTI, is currently
in a Phase 1/2 trial in combination with alpelisib for patients
with PIK3CA-dependent head and neck squamous cell carcinoma
(KURRENT-HN). Kura is also preparing to evaluate KO-2806, a
next-generation FTI, in a Phase 1 dose-escalation trial as a
monotherapy and in combination with other targeted therapies,
beginning with ccRCC and KRASG12C-mutant NSCLC (FIT-001). For
additional information, please visit Kura’s website at
www.kuraoncology.com and follow us on Twitter and LinkedIn.
Forward-Looking Statements
This news release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy,
safety and therapeutic potential of KO-2806, potential benefits of
combining KO-2806 with appropriate standards of care, and progress
and expected timing of the KO-2806 program and clinical trials.
Factors that may cause actual results to differ materially include
the risk that compounds that appeared promising in early research
or clinical trials do not demonstrate safety and/or efficacy in
later preclinical studies or clinical trials, the risk that Kura
may not obtain approval to market its product candidates,
uncertainties associated with performing clinical trials,
regulatory filings, applications and other interactions with
regulatory bodies, risks associated with reliance on third parties
to successfully conduct clinical trials, the risks associated with
reliance on outside financing to meet capital requirements, and
other risks associated with the process of discovering, developing
and commercializing drugs that are safe and effective for use as
human therapeutics, and in the endeavor of building a business
around such drugs. You are urged to consider statements that
include the words “may,” “will,” “would,” “could,” “should,”
“believes,” “estimates,” “projects,” “promise,” “potential,”
“expects,” “plans,” “anticipates,” “intends,” “continues,”
“designed,” “goal,” or the negative of those words or other
comparable words to be uncertain and forward-looking. For a further
list and description of the risks and uncertainties the Company
faces, please refer to the Company's periodic and other filings
with the Securities and Exchange Commission (SEC), including the
Company’s Form 10-Q for the quarter ended June 30, 2023 filed with
the SEC on August 9, 2023, which are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and Kura assumes no obligation to update any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts
Investors:Pete De SpainExecutive Vice President,
Investor Relations &Corporate Communications(858)
500-8833pete@kuraoncology.com
Media:Alexandra WeingartenSenior Manager,
Corporate Communications(858)
500-8822alexandra@kuraoncology.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Apr 2024 to May 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From May 2023 to May 2024